

9. The medicament as claimed in claim 8, wherein the active substance comprises oligo- and/or polyribonucleotides from yeast cells.
10. The medicament as claimed in claims 6, wherein the active substance comprises xenogeneic tRNA.
11. The medicament as claimed in claim 6, wherein the active substance comprises xenogeneic oligo- and/or polyribonucleotides obtained by phenol extraction.
12. The medicament as claimed in claim 6, wherein the xenogeneic oligo- and/or polyribonucleotides originate from organisms which are evolutionarily distant from the organism to be treated.
13. The medicament as claimed in claim 6, wherein the oligo- and/or polyribonucleotides are present in an anhydrous form.
14. The medicament as claimed in claim 6, wherein it is present in a form suitable for topical administration..
15. A method for the treatment of infections by Herpesviridae and/or skin tumors in a subject comprising administering to the subject an active amount of 0.1 mg and higher of xenogeneic oligo- and/or polyribonucleotides per unit dose.
16. A pharmaceutical composition comprising xenogeneic oligo- and/or polyribonucleotides.
17. The pharmaceutical composition of claim 16, further comprising physiologically acceptable carriers, excipients, diluents and/or additives.
18. The pharmaceutical composition of claim 16 wherein said xenogeneic oligo- and/or polyribonucleotides originate from organisms which are evolutionarily distant from the organism to be treated.

19. A method for treating lesions of the skin and/or mucosa caused by herpes simplex virus and/or varicella zoster virus comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 25 to a subject in need thereof.

20. A method for the treatment of infections by Herpesviridae and/or skin tumors, comprising administering an active amount of 0.1 mg and higher of xenogeneic oligo- and/or polyribonucleotides in an anhydrous preparation per dose unit is administered once per recurrence to the subject..